Compare VYGR & INGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | INGN |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.3M | 177.1M |
| IPO Year | 2015 | 2013 |
| Metric | VYGR | INGN |
|---|---|---|
| Price | $3.40 | $5.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $16.50 | $11.25 |
| AVG Volume (30 Days) | ★ 404.1K | 211.0K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.42 |
| EPS | N/A | ★ N/A |
| Revenue | $10,135,000.00 | ★ $348,668,000.00 |
| Revenue This Year | $34.04 | $8.03 |
| Revenue Next Year | $7.92 | $7.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.86 |
| 52 Week Low | $2.94 | $5.29 |
| 52 Week High | $5.55 | $9.13 |
| Indicator | VYGR | INGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 28.11 |
| Support Level | $3.33 | N/A |
| Resistance Level | $3.56 | $6.73 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 74.03 | 8.18 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.